Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
Authors:
- Gabriela Rodríguez-MacíasGRGabriela Rodríguez-Macías
- Oscar BrizOscar Briz
- Candela Cives-LosadaCCCandela Cives-Losada
- María C. ChillónMCMaría C. Chillón
- Carolina Martínez-LapercheCMCarolina Martínez-Laperche
- Ibon Martínez-ArranzIMIbon Martínez-Arranz
- Ismael BuñoIBIsmael Buño
- Marcos González-DíazMGMarcos González-Díaz
- José L. Díez-MartínJDJosé L. Díez-Martín
- Jose J. G. MarinJose J. G. Marin
- Rocio I. R. MaciasRocio I. R. Macias
Open Access
Abstract
Despite its often low efficacy and high toxicity, the standard treatment for acute myeloid leukemia (AML) is induction chemotherapy with cytarabine and idarubicin. Here, we have investigated the role of transporters and drug-metabolizing enzymes in this poor outcome. The expression levels (RT-qPCR) of potentially responsible genes in blasts collected at diagnosis were related to the subsequent response to two-cycle induction chemotherapy. The high expression of uptake carriers (ENT2), export ATP-binding cassette (ABC) pumps (MDR1), and enzymes (DCK, 5-NT, and CDA) in the blasts was associated with a lower response. Moreover, the sensitivity to cytarabine in AML cell lines was associated with ENT2 expression, whereas the expression of ABC pumps and enzymes was reduced. No ability of any AML cell line to export idarubicin through the ABC pumps, MDR1 and MRP, was found. The exposure of AML cells to cytarabine or idarubicin upregulated the detoxifying enzymes (5-NT and DCK). In AML patients, 5-NT and DCK expression was associated with the lack of response to induction chemotherapy (high sensitivity and specificity). In conclusion, in the blasts of AML patients, the reduction of the intracellular concentration of the active metabolite of cytarabine, mainly due to the increased expression of inactivating enzymes, can determine the response to induction chemotherapy.Keywords
Funding Information
- Consejería de Educación, Junta de Castilla y León (BIO/SA52/15, Call 2015, PI20/00189, PI19/00819)
- Fundación Mutua Madrileña (BIO/SA52/15, Call 2015, PI20/00189, PI19/00819)
- Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (BIO/SA52/15, Call 2015, PI20/00189, PI19/00819)
- Ministry of Science, Innovation, and Universitie (BIO/SA52/15, Call 2015, PI20/00189, PI19/00819)
This publication has 39 references indexed in Scilit:
- Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trialBlood Cancer Journal, 2011
- Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cellsBiochemical Pharmacology, 2009
- Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term SurvivalClinical Cancer Research, 2009
- NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced CardiotoxicityCirculation, 2005
- Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanismBiochemical Pharmacology, 2005
- MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemiaBritish Journal of Haematology, 2005
- Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid LeukemiasClinical Cancer Research, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Five putative drug resistance parameters (MDR1/P‐glycoprotein, MDR‐associated protein, glutathione‐S‐transferase, bcl‐2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemiasEuropean Journal of Haematology, 1997
- P‐glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survivalBritish Journal of Haematology, 1994